169 related articles for article (PubMed ID: 38213540)
1. Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy.
Laopajon W; Takheaw N; Kotemul K; Pata S; Hongeng S; Kasinrerk W
Explor Target Antitumor Ther; 2023; 4(6):1145-1156. PubMed ID: 38213540
[TBL] [Abstract][Full Text] [Related]
2. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
3. Generation and Characterization of a Human/Mouse Chimeric GD2-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma.
Eger C; Siebert N; Seidel D; Zumpe M; Jüttner M; Brandt S; Müller HP; Lode HN
PLoS One; 2016; 11(3):e0150479. PubMed ID: 26967324
[TBL] [Abstract][Full Text] [Related]
4. IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.
Stip MC; Evers M; Nederend M; Chan C; Reiding KR; Damen MJ; Heck AJR; Koustoulidou S; Ramakers R; Krijger GC; de Roos R; Souteyrand E; Cornel AM; Dierselhuis MP; Jansen M; de Boer M; Valerius T; van Tetering G; Leusen JHW; Meyer-Wentrup F
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37479484
[TBL] [Abstract][Full Text] [Related]
5. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy.
Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T
Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922
[TBL] [Abstract][Full Text] [Related]
6. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
7. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
[TBL] [Abstract][Full Text] [Related]
8. Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth.
Li SL; Liang SJ; Guo N; Wu AM; Fujita-Yamaguchi Y
Cancer Immunol Immunother; 2000 Jul; 49(4-5):243-52. PubMed ID: 10941907
[TBL] [Abstract][Full Text] [Related]
9. Chimerism of avian IgY-scFv and truncated IgG-Fc: A novel strategy in cross-species antibody generation and enhancement.
Ge S; Dias ACP; Zhang X
Immunology; 2024 May; 172(1):46-60. PubMed ID: 38247105
[TBL] [Abstract][Full Text] [Related]
10. Construction, purification, and characterization of anti-BAFF scFv-Fc fusion antibody expressed in CHO/dhfr- cells.
Cao M; Cao P; Yan H; Lu W; Ren F; Hu Y; Zhang S
Appl Biochem Biotechnol; 2009 Jun; 157(3):562-74. PubMed ID: 19099209
[TBL] [Abstract][Full Text] [Related]
11. Interference of HCV replication by cell penetrable human monoclonal scFv specific to NS5B polymerase.
Thueng-in K; Thanongsaksrikul J; Jittavisutthikul S; Seesuay W; Chulanetra M; Sakolvaree Y; Srimanote P; Chaicumpa W
MAbs; 2014; 6(5):1327-39. PubMed ID: 25517317
[TBL] [Abstract][Full Text] [Related]
12. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
[TBL] [Abstract][Full Text] [Related]
13. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
14. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
15. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy.
Cheng M; Ahmed M; Xu H; Cheung NK
Int J Cancer; 2015 Jan; 136(2):476-86. PubMed ID: 24895182
[TBL] [Abstract][Full Text] [Related]
16. Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.
Hristodorov D; Mladenov R; Brehm H; Fischer R; Barth S; Thepen T
MAbs; 2014; 6(5):1283-9. PubMed ID: 25517313
[TBL] [Abstract][Full Text] [Related]
17. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors.
Cheng M; Santich BH; Xu H; Ahmed M; Huse M; Cheung NK
Oncoimmunology; 2016 Jun; 5(6):e1168557. PubMed ID: 27471647
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of dimeric small immunoproteins specific for neuroblastoma associated antigen GD2.
Occhino M; Raffaghello L; Burrone O; Gambini C; Pistoia V; Corrias MV; Bestagno M
Int J Mol Med; 2004 Sep; 14(3):383-8. PubMed ID: 15289889
[TBL] [Abstract][Full Text] [Related]
19. A mutated anti-CA19-9 scFv-Fc for positron emission tomography of human pancreatic cancer xenografts.
Rochefort MM; Girgis MD; Knowles SM; Ankeny JS; Salazar F; Wu AM; Tomlinson JS
Mol Imaging Biol; 2014 Oct; 16(5):721-9. PubMed ID: 24691872
[TBL] [Abstract][Full Text] [Related]
20. Preclinical Evaluation of an Engineered Single-Chain Fragment Variable-Fragment Crystallizable Targeting Human CD44.
Diebolder P; Mpoy C; Scott J; Huynh TT; Fields R; Spitzer D; Bandara N; Rogers BE
J Nucl Med; 2021 Jan; 62(1):137-143. PubMed ID: 32513906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
